logo
Plus   Neg
Share
Email

Moderna' COVID-19 Vaccine Trial Shows Strong Immune Responses

Shares of Moderna Inc (MRNA) jumped 17% in after hours trading on Tuesday after the company's experimental vaccine for COVID-19 demonstrated it was safe and induced rapid and strong immune responses against the virus.

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of Medicine.

The interim analysis evaluated a two-dose vaccination schedule of mRNA-1273 given 28 days apart across three dose levels in 45 healthy adult participants ages 18-55 years.

Participants in the initial dose cohorts who received both vaccinations and were evaluated at pre-specified timepoints reaffirm the positive interim data assessment and show mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2.

mRNA-1273 was generally safe and well-tolerated, with no serious adverse events reported.

The study was led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT